Sun J, Rajsbaum R, Yi M. Immune and non-immune responses to hepatitis C virus infection. World J Gastroenterol 2015; 21(38): 10739-10748 [PMID: 26478666 DOI: 10.3748/wjg.v21.i38.10739]
Corresponding Author of This Article
Jiaren Sun, MD, PhD, Department of Microbiology and Immunology, Institute for Human Infections and Immunity, University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77555-1070, United States. jisun@utmb.edu
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Topic Highlight
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Oct 14, 2015; 21(38): 10739-10748 Published online Oct 14, 2015. doi: 10.3748/wjg.v21.i38.10739
Immune and non-immune responses to hepatitis C virus infection
Jiaren Sun, Ricardo Rajsbaum, MinKyung Yi
Jiaren Sun, Ricardo Rajsbaum, MinKyung Yi, Department of Microbiology and Immunology, Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX 77555-1070, United States
Author contributions: Sun J, Rajsbaum R and Yi M analyzed the literature and wrote the manuscript.
Supported by NIH AI109100 (to Sun J), R01AI110358 (to Yi M); and UTMB Institute for Human Infection and Immunity and UT System Rising STAR Award (to Rajsbaum R).
Conflict-of-interest statement: The authors have no conflict of interest to report.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Jiaren Sun, MD, PhD, Department of Microbiology and Immunology, Institute for Human Infections and Immunity, University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77555-1070, United States. jisun@utmb.edu
Telephone: +1-409-7470186 Fax: +1-409-7476869
Received: May 18, 2015 Peer-review started: May 20, 2015 First decision: June 23, 2015 Revised: July 6, 2015 Accepted: September 14, 2015 Article in press: September 14, 2015 Published online: October 14, 2015 Processing time: 148 Days and 21 Hours
Core Tip
Core tip: Hepatitis C virus (HCV) is an etiologic agent that can cause severe liver diseases, including chronic hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma. Although newly available direct-acting antivirals (DAAs) are very effective in viral clearance in patients, it remains unclear as to how many of the world’s infected individuals will benefit from the new DAAs. In this review, we focus on recent studies that address the host responses critical for viral clearance and disease resolution. Additional discussion is devoted to the prophylactic vaccine development and innate responses against HCV infection. Current theories on how the ubiquitin system and interferon-stimulated genes may affect HCV replication are also discussed.
